Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL887397 | 0.76 | ALDH1A1 (0.40) | CA12CA1CA9CYP3A4MEN1 | |
| SCHEMBL887390 | 0.73 | HKDC1 (0.31) | HPGDGAAKDM4ELMNA | |
| SCHEMBL887292 | 0.71 | GPR84 (0.50) | GPR84KDM4EMAPTWDR5DNMT1 | |
| SCHEMBL887355 | 0.65 | GPR84 (0.43) | HPGDGAAPOLBGPR84KDM4E | |
| SCHEMBL887284 | 0.63 | GPR84 (0.65) | HPGDGPR84KDM4EWDR5MEN1 | |
| SCHEMBL20554922 | 0.61 | HPGD (0.48) | HPGDGAAPOLBCA12CA1 | |
| SCHEMBL2523778 | 0.60 | HPGD (0.56) | HPGDGAAPOLBKDM4E | |
| SCHEMBL4265934 | 0.60 | CYP3A4 (0.40) | HPGDCA12CA1CA9KDM4E | |
| SCHEMBL4266742 | 0.59 | HPGD (0.68) | HPGDGAAPOLBCA12CA1 | |
| SCHEMBL4371294 | 0.59 | HPGD (0.56) | HPGDCA12CA1CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902207-B2 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| US-20070142639-A1 | Process for production of amines | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142639-A1 | Process for production of amines | SMS, CCNT1, PEAK1 | HPGD 2901/4885GAA 2259/4885POLB 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.